| abstract |
The present invention provides materials and methods for promoting weight loss or preventing weight gain and in the treatment of diabetes and related metabolic disorders. In particular, the present invention provides novel acylated glucagon analog peptides that are effective in such methods. The peptides of the present application can mediate their effects by having an increased selectivity for the GLP-1 receptor compared to human glucagon. |